Mpox Patient Journey in Israel
Reports on Mpox have, thus far, characterized the disease, but mostly through a single timepoint view. The aim of this study was to characterize Mpox in the Israeli setting, in general, alongside compiling a detailed patient journey from multiple in-depth interviews with infected individuals. This d...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/11/4/1042 |
| _version_ | 1827744321969848320 |
|---|---|
| author | Tal Patalon Galit Perez Yaki Saciuk Ziva Refaeli Sivan Gazit |
| author_facet | Tal Patalon Galit Perez Yaki Saciuk Ziva Refaeli Sivan Gazit |
| author_sort | Tal Patalon |
| collection | DOAJ |
| description | Reports on Mpox have, thus far, characterized the disease, but mostly through a single timepoint view. The aim of this study was to characterize Mpox in the Israeli setting, in general, alongside compiling a detailed patient journey from multiple in-depth interviews with infected individuals. This descriptive study followed two complimentary paths: retrospective and prospective. The first consisted of interviews with Mpox patients, while the retrospective part included the retrieval of anonymized electronic medical records of patients diagnosed with Mpox between May and November 2022. Patient characteristics in Israel were, overall, comparable to global reports. We found that the median time from symptoms to first suspicion of Mpox was 3.5 days, while the median time from the first symptom to a confirmatory test was 6.5 days, which could explain the surge in Israel. The duration of lesions did not alter in terms of their anatomical location, while lower Ct values correlated both with a longer symptom duration and more symptoms. Most patients reported anxiety to a high degree. Clinical trials that consist of a long-term relationship with the medical researchers contribute greatly to a deeper understanding of the patient journey, especially for unfamiliar or stigmatized diseases. Emerging infections, such as Mpox, should be further investigated to assess asymptomatic carriers, especially when rapidly spreading. |
| first_indexed | 2024-03-11T04:43:03Z |
| format | Article |
| id | doaj.art-f51fdbd129e34502a2c13e22b585f1f7 |
| institution | Directory Open Access Journal |
| issn | 2076-2607 |
| language | English |
| last_indexed | 2024-03-11T04:43:03Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj.art-f51fdbd129e34502a2c13e22b585f1f72023-11-17T20:34:11ZengMDPI AGMicroorganisms2076-26072023-04-01114104210.3390/microorganisms11041042Mpox Patient Journey in IsraelTal Patalon0Galit Perez1Yaki Saciuk2Ziva Refaeli3Sivan Gazit4Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv 68125, IsraelMaccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv 68125, IsraelKahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv 68125, IsraelMaccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv 68125, IsraelKahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv 68125, IsraelReports on Mpox have, thus far, characterized the disease, but mostly through a single timepoint view. The aim of this study was to characterize Mpox in the Israeli setting, in general, alongside compiling a detailed patient journey from multiple in-depth interviews with infected individuals. This descriptive study followed two complimentary paths: retrospective and prospective. The first consisted of interviews with Mpox patients, while the retrospective part included the retrieval of anonymized electronic medical records of patients diagnosed with Mpox between May and November 2022. Patient characteristics in Israel were, overall, comparable to global reports. We found that the median time from symptoms to first suspicion of Mpox was 3.5 days, while the median time from the first symptom to a confirmatory test was 6.5 days, which could explain the surge in Israel. The duration of lesions did not alter in terms of their anatomical location, while lower Ct values correlated both with a longer symptom duration and more symptoms. Most patients reported anxiety to a high degree. Clinical trials that consist of a long-term relationship with the medical researchers contribute greatly to a deeper understanding of the patient journey, especially for unfamiliar or stigmatized diseases. Emerging infections, such as Mpox, should be further investigated to assess asymptomatic carriers, especially when rapidly spreading.https://www.mdpi.com/2076-2607/11/4/1042MpoxMPXmonkeypoxpatient journeyOrthopoxvirus genus |
| spellingShingle | Tal Patalon Galit Perez Yaki Saciuk Ziva Refaeli Sivan Gazit Mpox Patient Journey in Israel Microorganisms Mpox MPX monkeypox patient journey Orthopoxvirus genus |
| title | Mpox Patient Journey in Israel |
| title_full | Mpox Patient Journey in Israel |
| title_fullStr | Mpox Patient Journey in Israel |
| title_full_unstemmed | Mpox Patient Journey in Israel |
| title_short | Mpox Patient Journey in Israel |
| title_sort | mpox patient journey in israel |
| topic | Mpox MPX monkeypox patient journey Orthopoxvirus genus |
| url | https://www.mdpi.com/2076-2607/11/4/1042 |
| work_keys_str_mv | AT talpatalon mpoxpatientjourneyinisrael AT galitperez mpoxpatientjourneyinisrael AT yakisaciuk mpoxpatientjourneyinisrael AT zivarefaeli mpoxpatientjourneyinisrael AT sivangazit mpoxpatientjourneyinisrael |